PriceTargets.com logo

R1 RCM - RCM Stock Price Target and Predictions

  • Consensus Rating: Moderate Buy
  • Consensus Price Target: $19.11
  • Forecasted Upside: 26.78%
  • Number of Analysts: 16
  • Breakdown:
  • 0 Sell Ratings
  • 2 Hold Ratings
  • 14 Buy Ratings
  • 0 Strong Buy Ratings
$15.07 As of 09/27/2023 01:00 AM ET
+0 (0.00%)

This chart shows the closing price for RCM by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New R1 RCM Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for RCM and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for RCM

Analyst Price Target is $19.11
▲ +26.78% Upside Potential
This price target is based on 16 analysts offering 12 month price targets for R1 RCM in the last 3 months. The average price target is $19.11, with a high forecast of $25.00 and a low forecast of $10.00. The average price target represents a 26.78% upside from the last price of $15.07.

This chart shows the closing price for RCM for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Moderate Buy

The current consensus among 16 contributing investment analysts is to moderate buy stock in R1 RCM. This Moderate Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 14 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
4/5/2022
  • 0 strong buy ratings
  • 14 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
7/4/2022
  • 0 strong buy ratings
  • 14 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
10/2/2022
  • 0 strong buy ratings
  • 14 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
12/31/2022
  • 0 strong buy ratings
  • 14 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
3/31/2023
  • 0 strong buy ratings
  • 14 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
6/29/2023
  • 0 strong buy ratings
  • 14 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
8/28/2023
  • 0 strong buy ratings
  • 14 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
9/27/2023

Latest Recommendations

  • 0 strong buy ratings
  • 14 buy ratings
  • 2 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
9/22/2023Royal Bank of CanadaReiterated RatingOutperform ➝ Outperform$22.00Low
9/22/2023CitigroupInitiated CoverageBuy$20.00Low
8/15/2023Cantor FitzgeraldInitiated CoverageOverweight$20.00Low
8/3/2023Morgan StanleyBoost TargetEqual Weight ➝ Equal Weight$16.00 ➝ $19.00Low
8/3/2023BarclaysBoost TargetOverweight ➝ Overweight$18.00 ➝ $20.00Low
7/21/2023GuggenheimReiterated RatingBuy ➝ Buy$21.00Low
6/16/2023Jefferies Financial GroupBoost Target$20.00 ➝ $22.00Low
6/15/2023Royal Bank of CanadaBoost Target$18.00 ➝ $22.00Low
5/19/2023Bank of AmericaBoost Target$19.00 ➝ $22.00Low
5/8/2023Deutsche Bank AktiengesellschaftBoost Target$16.00 ➝ $18.00Low
4/13/2023Bank of AmericaBoost TargetBuy$17.50 ➝ $19.00Low
4/11/2023StephensInitiated CoverageOverweight$18.00Low
4/11/2023Robert W. BairdInitiated CoverageOutperform$18.00Low
2/17/2023Canaccord Genuity GroupBoost TargetBuy$17.00 ➝ $21.00Low
2/17/2023Deutsche Bank AktiengesellschaftBoost Target$14.00 ➝ $16.00Low
2/2/2023Royal Bank of CanadaBoost TargetOutperform$14.00 ➝ $18.00Low
2/2/2023KeyCorpBoost TargetOverweight$15.00 ➝ $20.00Low
2/2/2023Truist FinancialDowngradeBuy ➝ Hold$15.00Low
1/18/2023BarclaysBoost TargetOverweight$12.00 ➝ $16.00Low
1/5/2023Canaccord Genuity GroupInitiated CoverageBuy$14.00Low
12/7/2022GuggenheimUpgradeNeutral ➝ Buy$15.00Low
12/6/2022Royal Bank of CanadaBoost TargetOutperform$12.00 ➝ $14.00Low
12/6/2022Morgan StanleyInitiated CoverageEqual Weight$11.00Low
12/5/2022KeyCorpBoost TargetOverweight$10.00 ➝ $15.00Low
11/18/2022JPMorgan Chase & Co.Lower TargetOverweight$33.00 ➝ $11.00Low
11/15/2022Evercore ISILower Target$10.00Low
11/15/2022BarclaysLower Target$12.00Low
11/14/2022CowenLower Target$34.00 ➝ $25.00Low
11/14/2022CowenLower TargetOutperform$34.00 ➝ $25.00Low
11/10/2022Deutsche Bank AktiengesellschaftLower Target$31.00 ➝ $14.00Low
11/9/2022SVB LeerinkLower TargetOutperform$35.00 ➝ $16.00Low
11/9/2022Royal Bank of CanadaLower TargetOutperform$35.00 ➝ $12.00Low
11/9/2022KeyCorpLower TargetOverweight$30.00 ➝ $10.00Low
10/23/2022Evercore ISIInitiated CoverageOutperform$25.00Low
9/15/2022KeyCorpInitiated CoverageOverweight$30.00Low
9/7/2022Truist FinancialInitiated CoverageBuy$29.00Low
8/4/2022Deutsche Bank AktiengesellschaftBoost Target$26.00 ➝ $31.00Low
8/1/2022JPMorgan Chase & Co.Initiated CoverageOverweight ➝ OverweightLow
6/29/2022Deutsche Bank AktiengesellschaftLower TargetBuy$28.00 ➝ $26.00Low
6/29/2022BarclaysReiterated RatingOverweight ➝ Overweight$29.00Low
5/10/2022Deutsche Bank AktiengesellschaftLower Target$30.00 ➝ $28.00Medium
4/13/2022GuggenheimInitiated CoverageNeutralHigh
3/3/2022Robert W. BairdBoost Target$29.00 ➝ $32.00Medium
2/9/2022Deutsche Bank AktiengesellschaftInitiated CoverageBuy$30.00Medium
12/13/2021CowenLower TargetOutperform ➝ Outperform$37.00 ➝ $34.00Low
12/1/2021Jefferies Financial GroupInitiated CoverageBuy$28.00Low
10/14/2021JPMorgan Chase & Co.Initiated CoverageOverweight$27.00Low
9/30/2021BarclaysInitiated CoverageOverweight$28.00High
8/19/2021Robert W. BairdReiterated RatingBuyHigh
7/22/2021Bank of AmericaInitiated CoverageBuy$27.00Low
6/2/2021Robert W. BairdInitiated CoverageOutperform$30.00Medium
5/27/2021SVB LeerinkReiterated RatingBuyHigh
2/16/2021KeyCorpBoost Target$27.00 ➝ $35.00Low
2/9/2021CowenBoost TargetOutperform$22.00 ➝ $33.00Low
1/6/2021KeyCorpBoost TargetOverweight$24.00 ➝ $26.00N/A
12/9/2020Royal Bank of CanadaBoost TargetOutperform$20.00 ➝ $27.00Low
12/3/2020SVB LeerinkBoost TargetOutperform$22.00 ➝ $26.00Medium
11/4/2020Cantor FitzgeraldBoost TargetOverweight$18.00 ➝ $22.00Medium
11/4/2020SVB LeerinkBoost TargetOutperform$18.00 ➝ $22.00Medium
11/2/2020KeyCorpBoost TargetOverweight$17.00 ➝ $24.00High
8/5/2020SVB LeerinkUpgradeMarket Perform ➝ Outperform$14.00 ➝ $18.00Medium
7/14/2020KeyCorpBoost TargetOverweight$12.00 ➝ $15.00Medium
4/20/2020Royal Bank of CanadaInitiated CoverageOutperform$12.00High
4/13/2020SVB LeerinkInitiated CoverageMarket Perform$10.00Medium
1/21/2020Cantor FitzgeraldReiterated RatingOverweight$15.00 ➝ $17.00High
1/14/2020KeyCorpBoost TargetOverweight$14.00 ➝ $15.00Low
1/10/2020Dougherty & CoInitiated CoverageBuy$15.00Medium
9/12/2019Robert W. BairdSet TargetBuy$14.00Low
4/12/2019Cantor FitzgeraldBoost TargetOverweight$11.00 ➝ $13.00Medium
1/22/2019KeyCorpInitiated CoverageOverweight ➝ Overweight$10.00High
12/10/2018CitigroupInitiated CoverageBuy ➝ Buy$20.00Medium
(Data available from 9/27/2018 forward)

News Sentiment Rating

1.00 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 13 very positive mentions
  • 15 positive mentions
  • 4 negative mentions
  • 1 very negative mentions
Mentions as of
3/1/2023
  • 6 very positive mentions
  • 14 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
3/31/2023
  • 3 very positive mentions
  • 21 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
4/30/2023
  • 12 very positive mentions
  • 17 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
5/30/2023
  • 9 very positive mentions
  • 7 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
6/29/2023
  • 4 very positive mentions
  • 7 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
7/29/2023
  • 11 very positive mentions
  • 9 positive mentions
  • 3 negative mentions
  • 0 very negative mentions
Mentions as of
8/28/2023
  • 9 very positive mentions
  • 6 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
9/27/2023

Current Sentiment

  • 9 very positive mentions
  • 6 positive mentions
  • 1 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

Positive

Very Positive

R1 RCM logo
R1 RCM Inc. provides technology-driven solutions that transform the patient experience and financial performance of hospitals, health systems, and physician groups. It offers end-to-end revenue cycle management (RCM) services, which address the spectrum of revenue cycle challenges faced by healthcare providers. The company provides modular services, including physician advisory services, which assists healthcare organizations in complying with payer requirements regarding whether to classify a hospital visit as an in-patient or an out-patient observation case for billing purposes; practice management services that offers administrative and operational support for patient care and outsource non-core functions; revenue integrity solutions, including coding management services, such as business intelligence and analysis, human capital management, accountability framework, and quality management programs; patient experience; and business office services. R1 RCM Inc. was founded in 2003 and is headquartered in Murray, Utah.
Read More

Today's Range

Now: $15.07
Low: $14.70
High: $15.19

50 Day Range

MA: $16.68
Low: $15.07
High: $18.22

52 Week Range

Now: $15.07
Low: $6.71
High: $19.46

Volume

3,224,928 shs

Average Volume

2,522,497 shs

Market Capitalization

$6.31 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.84

Frequently Asked Questions

What sell-side analysts currently cover shares of R1 RCM?

The following sell-side analysts have issued stock ratings on R1 RCM in the last twelve months: Bank of America Co., Barclays PLC, Canaccord Genuity Group Inc., Cantor Fitzgerald, Citigroup Inc., Cowen Inc, Cowen Inc., Deutsche Bank Aktiengesellschaft, Evercore ISI, Guggenheim, Jefferies Financial Group Inc., JPMorgan Chase & Co., KeyCorp, Morgan Stanley, Robert W. Baird, Royal Bank of Canada, Stephens, SVB Leerink LLC, TheStreet, and Truist Financial Co..
View the latest analyst ratings for RCM.

What is the current price target for R1 RCM?

19 Wall Street analysts have set twelve-month price targets for R1 RCM in the last year. Their average twelve-month price target is $19.11, suggesting a possible upside of 26.8%. Cowen Inc. has the highest price target set, predicting RCM will reach $25.00 in the next twelve months. Evercore ISI has the lowest price target set, forecasting a price of $10.00 for R1 RCM in the next year.
View the latest price targets for RCM.

What is the current consensus analyst rating for R1 RCM?

R1 RCM currently has 2 hold ratings and 14 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Moderate Buy."
View the latest ratings for RCM.

What other companies compete with R1 RCM?

Other companies that are similar to R1 RCM include SPS Commerce, Core & Main, Duolingo, Genpact and FTI Consulting. Learn More about companies similar to R1 RCM.

How do I contact R1 RCM's investor relations team?

R1 RCM's physical mailing address is 401 NORTH MICHIGAN AVENUE SUITE 2700, CHICAGO IL, 60611. The healthcare provider's listed phone number is (312) 324-7820 and its investor relations email address is [email protected]. The official website for R1 RCM is www.r1rcm.com. Learn More about contacing R1 RCM investor relations.